HYALURONIDASE-OCSQ\OCRELIZUMAB: 171 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
171
Total FAERS Reports
0
Deaths Reported
7
Hospitalizations
171
As Primary/Secondary Suspect
First Report: 20220101 · Latest Report: 20250919
What Are the Most Common HYALURONIDASE-OCSQ\OCRELIZUMAB Side Effects?
#1 Most Reported
Injection site erythema
23 reports (13.5%)
#2 Most Reported
Off label use
21 reports (12.3%)
#3 Most Reported
Injection site pain
20 reports (11.7%)
All HYALURONIDASE-OCSQ\OCRELIZUMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Injection site erythema | 23 | 13.5% | 0 | 2 |
| Off label use | 21 | 12.3% | 0 | 1 |
| Injection site pain | 20 | 11.7% | 0 | 2 |
| Contusion | 17 | 9.9% | 0 | 1 |
| Fatigue | 17 | 9.9% | 0 | 0 |
| No adverse event | 13 | 7.6% | 0 | 0 |
| Pain | 13 | 7.6% | 0 | 0 |
| Erythema | 12 | 7.0% | 0 | 0 |
| Injection site reaction | 12 | 7.0% | 0 | 0 |
| Headache | 10 | 5.9% | 0 | 0 |
| Injection site swelling | 10 | 5.9% | 0 | 2 |
| Rash | 10 | 5.9% | 0 | 0 |
| Swelling | 8 | 4.7% | 0 | 0 |
| Pain in extremity | 7 | 4.1% | 0 | 0 |
| Multiple sclerosis relapse | 6 | 3.5% | 0 | 1 |
| Abdominal pain | 5 | 2.9% | 0 | 1 |
| Asthenia | 5 | 2.9% | 0 | 0 |
| Diarrhoea | 5 | 2.9% | 0 | 0 |
| Gait disturbance | 5 | 2.9% | 0 | 1 |
| Injection site pruritus | 5 | 2.9% | 0 | 0 |
Who Reports HYALURONIDASE-OCSQ\OCRELIZUMAB Side Effects? Age & Gender Data
Gender: 73.8% female, 26.2% male. Average age: 45.4 years. Most reports from: US. View detailed demographics →
Is HYALURONIDASE-OCSQ\OCRELIZUMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2022 | 1 | 0 | 0 |
| 2023 | 1 | 0 | 1 |
| 2024 | 15 | 0 | 2 |
| 2025 | 54 | 0 | 1 |
What Is HYALURONIDASE-OCSQ\OCRELIZUMAB Used For?
| Indication | Reports |
|---|---|
| Multiple sclerosis | 65 |
| Product used for unknown indication | 41 |
| Relapsing multiple sclerosis | 32 |
| Relapsing-remitting multiple sclerosis | 20 |
| Primary progressive multiple sclerosis | 14 |
HYALURONIDASE-OCSQ\OCRELIZUMAB vs Alternatives: Which Is Safer?
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYALURONIDASE \RITUXIMAB
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYALURONIDASE-ZZXF\PERTUZUMAB\TRASTUZUMAB
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDRALAZINE
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDRALAZINE\ISOSORBIDE DINITRATE
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE\IRBESARTAN
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE\LISINOPRIL
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE\LOSARTAN
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE\METOPROLOL
HYALURONIDASE-OCSQ\OCRELIZUMAB vs HYDROCHLOROTHIAZIDE\NEBIVOLOL
Official FDA Label for HYALURONIDASE-OCSQ\OCRELIZUMAB
Official prescribing information from the FDA-approved drug label.